GRA Enterprises

Biotech clinical-stage company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has closed its previously announced non-brokered private placement for a total of 373,900 of its units at $3.75 per share, for gross proceeds of $1,402,125.  Algernon focuses on investigating new disease applications...